Experimental RNA vaccine takes on advanced lung cancer
NCT ID NCT07561723
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new RNA vaccine called IMP3-saRNA (YMN-136) in 9 people with advanced non-small cell lung cancer who have run out of standard options. The vaccine aims to train the immune system to attack cancer cells that carry a specific marker (IMP3). The main goal is to check safety, but researchers will also look for signs that the vaccine shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMP3-saRNA (YMN-136) vaccine
What this could lead to
If it works, this could point toward a new treatment option for advanced lung cancer that uses the immune system to fight tumors.
What could go wrong
This is a very early, small trial with only 9 people, so it may not show clear benefit. The vaccine could cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University, Chengdu, Sichuan
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••